Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases

BACKGROUND: The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] > 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatectomy following adjuvant apalutamid...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Gordon, Belkoff, Laurence, Hafron, Jason M., Saltzstein, Daniel R., Potdar, Rushikesh, Bhaumik, Amitabha, Phillips, Jennifer, McGowan, Tracy, Shore, Neal D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928932/
https://www.ncbi.nlm.nih.gov/pubmed/36472728
http://dx.doi.org/10.1007/s11523-022-00932-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928932/
https://www.ncbi.nlm.nih.gov/pubmed/36472728
http://dx.doi.org/10.1007/s11523-022-00932-8

Ejemplares similares